Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.86 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | UBE2N | P61088 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | HTR1D | P28221 | 1/20 | 0.57 |
| ▸ | HTR1B | P28222 | 1/20 | 0.57 |
| ▸ | HTR1F | P30939 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15250049 | 0.92 | HTR6 (1.00) | HTR6ALK | |
| SCHEMBL31366254 | 0.88 | HTR6 (0.73) | HTR6ALKKDM4EUBE2NCYP19A1 | |
| SCHEMBL16375238 | 0.86 | HTR6 (0.79) | HTR6ALKKDM4EUBE2NCYP19A1 | |
| SCHEMBL28930519 | 0.85 | HTR6 (0.70) | HTR6ALKKDM4EUBE2NCYP19A1 | |
| SCHEMBL27936448 | 0.85 | HTR6 (0.77) | HTR6ALKKDM4EUBE2NCYP19A1 | |
| SCHEMBL946516 | 0.83 | HTR6 (0.74) | HTR6ALKKDM4EUBE2NCYP19A1 | |
| SCHEMBL28244706 | 0.82 | HTR6 (0.73) | HTR6ALKKDM4EUBE2NCYP19A1 | |
| SCHEMBL12700490 | 0.82 | HTR6 (0.72) | HTR6ALKKDM4EUBE2NCYP19A1 | |
| SCHEMBL945595 | 0.82 | HTR6 (0.72) | HTR6ALKKDM4EUBE2NCYP19A1 | |
| SCHEMBL2132873 | 0.82 | HTR6 (0.72) | HTR6ALKKDM4EUBE2NCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5463105-A | Therapy for cardiovascular, nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1995-10-31 | — | — | US | disclosed |
| US-5298513-A | Serotonin antagonist | BAYER AKTIENGESELLSCHAFT (DE) | 1994-03-29 | — | — | US | disclosed |
| EP-0270947-B1 | SUBSTITUTED BASIC 2-AMINOTETRALINES | BAYER AG (DE) | 1993-05-19 | — | — | EP | disclosed |
| US-5153225-A | For treating disorders of the central nervous system, cardiovascular system and intestinal tract | BAYER AKTIENGESELLSCHAFT (DE) | 1992-10-06 | — | — | US | disclosed |
| US-5026857-A | Cetnral nervous system disorders; antiserotonine agent | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-25 | — | — | US | disclosed |
| US-4880802-A | CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1989-11-14 | — | — | US | disclosed |
| EP-0270947-A2 | Substituted basic 2-aminotetralines | BAYER AG (DE) | 1988-06-15 | — | — | EP | disclosed |